The anticonvulsant topiramate (TPM) has been recently proposed as a novel adjuvant therapy for bipolar disorder and schizophrenia, yet its efficacy remains controversial. As both disorders are characterized by gating deficits, we tested the effects of TPM on the behavioral paradigm of prepulse inhibition (PPI) of the acoustic startle response, a validated animal model of sensorimotor gating. TPM (10, 18, 32, 58, 100 mg/kg, intraperitoneal, i.p.) enhanced PPI in rats in a dose-dependent fashion, prevented the PPI reduction mediated by the dopaminergic agonist apomorphine (0.25 mg/kg, subcutaneous, s.c.) and potentiated the effects of the antipsychotic drugs haloperidol (0.05, 0.1 mg/kg, i.p.) and clozapine (2.5, 5 mg/kg, i.p.). Conversely, TPM elicited no significant effect on the PPI disruption mediated by the NMDA receptor antagonist dizocilpine (0.05, 0.1 mg/kg, s.c.) and surprisingly antagonized the attenuation of dizocilpine-induced PPI disruption mediated by clozapine (5 mg/kg, i.p.). Our results suggest that TPM may exert diverse actions on the neural substrates of sensorimotor gating. While the pharmacological mechanisms of such effects are still elusive, our findings might contribute to shed light on some controversies on the therapeutic action of TPM, and point to this drug as a putative novel adjuvant therapy for some clusters of gating disturbances.
INTRODUCTION
Topiramate (TPM, 2,3:4,5-bis-O-1-methylethylidene-beta-Dfructopyranose sulfate) is a novel therapeutic agent, currently indicated as adjunctive treatment for refractory partial-onset or primary generalized tonic-clonic seizures, as well as for migraine prophylaxis (Shank et al, 2000; Silberstein et al, 2005) . Although its mechanisms of action have not been fully elucidated, TPM is known to enhance the activity of g-aminobutyric acid (GABA) through interaction with GABA A receptors, as well as to block voltage-dependent sodium channels and kainate/ [alpha]-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptors (Schneiderman, 1998) . Emerging evidence indicates that TPM might offer promising applications for the therapy of other neurological conditions, such as neuropathic pain and essential tremor (Chong and Libretto, 2003; Connor, 2002) , as well as several psychiatric disorders, such as bipolar disorder (Calabrese et al, 2001; Grunze et al, 2001) , schizoaffective disorder (Deutsch et al, 2003) , posttraumatic disorder (Berlant and Van Kammen, 2002 ), Tourette's syndrome (Abuzzahab and Brown, 2001 ) and some clusters of schizophrenia (Drapalski et al, 2001) . The therapeutic potential of TPM for these disorders, however, is disputed on account of contrasting findings (Arnone, 2005; Millson et al, 2002) and in view of its numerous cognitive and affective side effects, such as depression, hallucinosis and cognitive deterioration (Matthews and Miller, 2001) . Thus, TPM has been alternately described to have therapeutic efficacy against negative symptoms in psychotic patients (Drapalski et al, 2001) and to produce paranoid delusions, auditory hallucinations, depersonalization, suicidal thoughts, aggressive behavior and severe mood swings (Khan et al, 1999; Stella et al, 2002; Mula et al, 2003) . Similarly, TPM has also been reported to either exacerbate (Kaplan, 2005) or treat manic disorders (Chengappa et al, 1999) . In spite of their distinct nosographic profiles and pathophysiological heterogeneity, both schizophrenia and bipolar disorderFlike most of the aforementioned psychiatric disorders putatively treated by TPMFdisplay a general alteration in sensorimotor gating (for a review, see Braff et al, 2001) , suggesting that TPM might actually modulate perceptual functions. Nevertheless, to the best of our knowledge, this hypothesis has not been tested to date. The aim of the present study was the elucidation of the effects of TPM on the behavioral paradigm of prepulse inhibition (PPI) of the acoustic startle response (ASR), a highly dependable model for the evaluation of sensorimotor gating . The PPI consists in the reduction of the startle reflex that occurs when the eliciting stimulus is immediately preceded by a prepulse, a weak, nonstartling prestimulus (Graham, 1975) . This physiological phenomenon can be typically disrupted in animals via several pharmacological treatments, mainly NMDA receptor antagonists, such as phencyclidine and dizocilpine, and dopaminergic agonists, such as amphetamine and apomorphine (for a review, see Geyer et al, 2001 ). It has also been shown that typical and atypical antipsychotics are effective in preventing PPI disruption mediated by dopaminergic agonists (Mansbach et al, 1988; Swerdlow et al, 1991) ; moreover, atypical, but not typical antipsychotics antagonize the PPI disruption caused by NMDA receptor antagonists (Geyer et al, 1990; Bakshi et al, 1994) . Specifically, we evaluated the effects of TPM, both alone and in cotreatment with haloperidol and clozapine, against the disruption of PPI induced by apomorphine and dizocilpine.
MATERIALS AND METHODS

Animals
Six hundred twenty-six male Sprague-Dawley albino rats (Harlan, Italy) weighing between 200 and 300 g served as subjects in the present study. Rats were housed four per cage in the animal care quarters, maintained at a temperature of 22721C on a reversed 12-h light-dark cycle (lights went off at 0700 and on at 1900). Food and water were available ad libitum, and each rat was handled for 5 min on each of the 5 days prior to experiment to minimize stress effects. All experimental procedures were approved by the local ethical committee and carried out in strict accordance with the Economic Community (EC) guidelines for care and use of experimental animals (86/609/ European EC).
Drugs and Chemicals
The following drugs were used: TPM, apomorphine hydrocloride, dizocilpine maleate, haloperidol, and clozapine. All drugs were purchased from Sigma Aldrich, Italy. Apomorphine was dissolved in 0.9% saline with 0.1 mg/ml ascorbic acid. TPM and dizocilpine were dissolved in 0.9% saline. Haloperidol was dissolved in 10% acetic acid buffered with sodium hydroxide (NaOH) and diluted with saline, while clozapine was dissolved in a single drop of 1 N chloridric acid (HCl) and diluted with saline. The pH was adjusted to seven using sodium bicarbonate (NaHCO 3 ). All drugs were weighed out as salts and administered in an injection volume of 1 ml/kg.
Apparatus
The apparatus for the detection of the startle reflexes (Med Associates, St Albans, Vermont) consisted of four standard cages placed in sound-attenuated chambers with fan ventilation. The cage was a Plexiglas cylinder of 9 cm diameter, mounted on a piezoelectric accelerometric platform connected to an analogue-digital converter. Background noise and acoustic bursts were conveyed by two separate speakers, placed at 7 cm beside the startle cage so as to produce a variation of sound within 1 dB across it. Both speakers and startle cages were connected to a main personal computer (PC), which detected and analyzed all chamber variables by means of custom software. Acoustic stimuli were monitored and balanced before each testing session through a digital sound level meter (Extech Instruments, Waltham, MA, USA), while the mechanical response of each cage was set and equalized in all chambers via a 10-Hz spinner calibrator provided by Med Associates.
Procedure
At 3 days before the experiment, all rats went through a brief baseline startle session. Rats were exposed to a background noise of 70 dB, and after an acclimatization period of 5 min, they were presented with a randomized sequence of 12 40 ms bursts of 115 dB, interposed with three trials in which a 82-dB prestimulus preceded the same pulse by 100 ms. Rats exhibiting baseline very high or very low startle values (more than two SD above or below group mean values) were excluded from the study. Subsequently, treatment groups were established so that the average startle response and percent PPI of each group were equivalent in all groups. On the testing day, each rat was placed in a cage for a 5-min acclimatization period with a 70-dB white noise background, which continued for the remainder of the session. Each session consisted of three consecutive sequences of trials (periods). Unlike the first and the third periods, during which rats were presented with only five pulse-alone trials of 115 dB, the second period consisted of a pseudorandom sequence of 50 trials, including 12 pulsealone trials; 30 trials of pulse preceded by 73-dB, 76-dB, or 82-dB prepulses (10 for each level of prepulse loudness); and eight no-stimulus trials, where only the background noise was delivered. Intertrial intervals (ITI) were selected randomly between 10 and 15 s. The startle session lasted about 30 min.
Experiment Description
This study consisted of seven experiments. In the first experiment (n ¼ 66; 6 groups of animals), we evaluated the intrinsic effect of TPM on PPI by treating animals with either 0.9% saline or TPM (10, 18, 32, 58, 100, intraperitoneal (i.p.) ). The second experiment (n ¼ 88; 8 groups of animals) was carried out to verify whether TPM (18, 32, 58 mg/kg, i.p.) prevents the PPI deficit induced by apomorphine (0.25 mg/kg, subcutaneous (s.c.)). Following the discovery that TPM reduces PPI disruption mediated by apomorphine, in the third and the fourth experiment (n ¼ 96; 12 groups of rats for each experiment) we tested whether this effect might be synergistic with the antipsychotic-like properties of haloperidol (0.05, 0.1 mg/kg i.p.) and clozapine (2.5, 5 mg/kg i.p.) to prevent apomorphinemediated PPI disruption. The fifth experiment (n ¼ 88, eight groups) was aimed at the evaluation of the action of TPM against dizocilpine-mediated PPI deficit. Subsequently, we tested whether the combination of TPM (32 mg/kg, i.p.) and haloperidol (0.1, 0.5 mg/kg, i.p.) was effective in reversing the PPI disruption mediated by dizocilpine (0.1 mg/kg, s.c.) (n ¼ 96; 12 groups of animals). Finally, the seventh experiment (n ¼ 96 rats, divided into 12 treatment groups), was performed to test the ability of the combination of TPM (32 mg/kg, i.p.) and clozapine (2.5, 5 mg/kg, i.p.) to antagonize PPI deficits induced by dizocilpine (0.1 mg/kg, s.c.), respectively. All substances were administered at a convenient time interval before experimental testing, compatible with their pharmacokinetic characteristics, so as to elicit their effects during the startle session. Table 1 presents a synopsis of the whole study, detailing the time intervals for each treatment in all the experiments.
Data Analysis
For each animal, the mean startle amplitudes for the first and the second halves of the second period of the session (blocks, six pulse-alone trials each) were analyzed with a two-way or three-way analysis of variance (ANOVA), with pretreatment (where present) and treatment as betweensubjects factors and blocks as repeated measures. The percent PPI was calculated with the following formula: 100À((mean startle amplitude for prepulse + pulse trials/ mean startle amplitude for pulse-alone trials) Â 100) and analyzed in multifactor ANOVAs (with specific design and comparisons noted below for each experiment) with the different combinations of injections for pretreatment and treatment as between-subjects factors and trial types as repeated measures. Post hoc analyses were performed using Tukey's test. Alpha was set at 0.05.
RESULTS
Throughout the study, no-stimulus trials data were found negligible in comparison with other startle values and nor were they affected by any drug treatment; therefore, they will not be presented here.
Effects of TPM
The first experiment was aimed at assessing the effects of TPM (TPM, 10, 18, 32, 58, 100 mg/kg, i.p.) on startle reflex and PPI, in comparison with saline. Startle magnitudes were evaluated using a two-way, repeated-measure ANOVA, with treatments and blocks as variables. As shown in . Post hoc analysis confirmed that the doses of 32, 58 and 100 mg/kg (i.p.) are able to enhance PPI levels in comparison with controls (po0.001 32 and 58 mg/kg, po0.01 100 mg/kg, in comparison with saline, Tukey's test). Interestingly, the doses of 10, 18, and 100 mg/kg i.p. appeared unable to significantly affect %PPI, thus outlining an inverse U-shaped effect of TPM on PPI (Figure 1 ). Finally, ANOVA showed a significant effect for prepulse intensity [F(2,120) ¼ 217.02; po0.001].
Effects of TPM Pretreatment vs Apomorphine
In the second experiment, we tested the effect of a TPM pretreatment (32, 58 mg/kg, i.p.) on the PPI disruption mediated by apomorphine (APO, 0.25 mg/kg, s.c.). Startle amplitudes were compared by a three-way ANOVA, with pretreatment and treatment as independent variables and blocks as repeated factors. In keeping with previous findings by our group (Bortolato et al, 2004) Table 2) . %PPI analysis, conducted by a second three-way, repeated-measure ANOVA, showed that apomorphine produced a dramatic reduction in PPI, as expected [F(1,80 Topiramate and prepulse inhibition R Frau et al Figure 2 , post hoc comparisons revealed that animals treated with TPM + saline exhibited an increased %PPI in comparison with the rats subjected to a double saline injection (po0.01 for each TPM dose, Tukey). Additionally, TPM pretreatment significantly reduced apomorphine-mediated PPI disruption at both doses (TPM + APO vs SAL + APO: po0.01 for both TPM doses, Tukey). Analyses of the differences between startle magnitudes on pulse-alone and prepulse + pulse trials (DPPI, see Bortolato et al, 2004) 
Effects of TPM in Combination with Haloperidol vs Apomorphine
Following the discovery that TPM can reduce the PPIdisruptive effects of apomorphine, we addressed the third experiment to the assessment of the ability of TPM (18 mg/ kg, i.p.) to potentiate the PPI effects of haloperidol (HAL, 0.05, 0.1 mg/kg, i.p.). Startle amplitudes were analyzed by a four-way ANOVA, with the three series of treatments as independent variables and blocks as repeated Figure 2 Effect of TPM pretreatment on the PPI disruption mediated by apomorphine. All TPM and apomorphine doses are given in mg/kg. Values represent mean7SEM for each treatment. Prepulses are indicated by the intensity corresponding to decibels above background noise. SAL, saline; TPM, TPM; APO, apomorphine; ### po0.001, ***po0.001 compared to SAL + SAL group; 111po0.01 compared to SAL + APO group. For further details, see text.
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showing that TPM was able to potentiate the antipsychoticlike effect of subthreshold dose of haloperidol. Parallel statistical analyses on DPPI confirmed that the restoration of PPI mediated by the combination of TPM and haloperidol is dissociated from effects on startle magnitude (data not shown).
Effects of TPM in Combination with Clozapine vs Apomorphine
The fourth experiment paralleled the previous one in evaluating the ability of TPM (18 mg/kg, i.p.) to potentiate the ability of clozapine (CLO, 2.5, 5 mg/kg, i.p.), in reversing the PPI disruption induced by apomorphine (0.25 mg/kg, s.c. interaction between the three series of treatments [F(2,84) ¼ 3.80, po0.05] . Post hoc analysis assessed that TPM significantly magnified the antipsychotic-like effect of the 2.5 mg/kg dose of clozapine (po0.05. Figure 4) . Comparisons between values of startle magnitude confirmed that such effect did not depend on the actions on startle magnitude (data not shown).
Effects of TPM Pretreatment vs Dizocilpine
The fifth experiment was performed to verify whether TPM (32, 58 mg/kg, i.p.) prevents dizocilpine (DIZ)-mediated PPI disruption. Startle amplitudes were evaluated with the same design as in the second experiment. ANOVA did not detect any significant effect, with the exception of a clear-cut habituation effect, as verified by the comparison between blocks [F(1,80) (Figure 5 ).
Effects of TPM in Combination with Haloperidol vs Dizocilpine
The sixth experiment evaluated the ability of the combination of TPM (32 mg/kg, i.p.) and haloperidol (0.1, 0.5 mg/kg, i.p.) in reversing the PPI disruption induced by dizocilpine (0.1 mg/kg, s.c.). Startle amplitudes were analyzed by a fourway ANOVA with treatments as independent variables and blocks as repeated measures. ANOVA showed only haloperidol was able to significantly blunt startle at both doses [F(2,84) ¼ 13.80, po0.001, ANOVA; po0.01 for both doses in comparison with saline, Tukey's test]. Besides, the comparison between trial blocks assessed a time-dependent attenuation in startle amplitude (F(1,84) ¼ 321.09, po0.001, Figure 1) . A further ANOVA, with the same independent variables and with PPI levels as repeated measures, served to test PPI values. ANOVA only revealed a significant effects for treatmentF[DIZ vs SAL: F(1,84) ¼ 1605.70, po0.0001] . A significant difference between prepulse levels was also found [F(2,168) ¼ 57.28, po0.001] (Figure 6 ).
Effects of TPM in Combination with Clozapine vs Dizocilpine
The last experiment evaluated the ability of TPM (32 mg/kg, i.p.) to interact with clozapine (2.5, 5 mg/kg i.p.), in reversing the PPI disruption induced by dizocilpine (0.25 mg/kg, s.c.). Startle amplitudes were analyzed by a four-way ANOVA with treatments as independent variables and blocks as repeated measures. ANOVA showed that clozapine was able to significantly attenuate startle amplitude [F(2,84) ¼ 21.94, po0.001]. ANOVA also showed a significant effect for blocks [F(1,84 Figure 7 , post hoc comparisons assessed that the treatment with clozapine (5 mg/kg, i.p.) significantly attenuated dizocilpine-mediated PPI disruption (po0.01, Tukey). Surprisingly, this effect was countered by TPM pretreatment (po0.01 for TPM + CLO + DIZ vs SAL + CLO + DIZ).
DISCUSSION
The results of the present study show that TPM affects startle response and sensorimotor gating in rats in a composite, polymorphous fashion. In detail, our findings suggest that this anticonvulsant, albeit able to reduce startle reflex at high dosages, enhances baseline prepulse inhibition within a dose range that does not interfere with startle Topiramate and prepulse inhibition R Frau et al responses. In parallel, TPM has been shown to significantly prevent the disruption of prepulse inhibition induced by the D 1 /D 2 dopamine receptor agonist apomorphine, but not by the noncompetitive NMDA receptor antagonist dizocilpine. TPM also potentiates the antipsychotic-like effects of haloperidol and clozapine in reversing apomorphinedependent PPI deficit. Conversely, the same drug fails to reverse PPI deficits induced by dizocilpine in combination with haloperidol, and even might arguably counter the ability of clozapine to attenuate this phenomenon.
Effects of TPM on Startle Reflex
TPM significantly altered startle amplitude at the dose of 100 mg/kg (i.p.), but not at any of the lower doses administered. As mentioned in the introduction, TPM produces a variety of inhibitory pharmacological and physiological effects relevant to acoustic startle response (ASR), including AMPA receptor antagonism (Gibbs et al, 2000) , blockade of voltage-gated Na + channels (Taverna et al, 1999) , and particularly GABA activation (White et al, 1997) . Assuming that the observed reduction in startle reflex may reflect the GABAergic mechanism of TPM, our data appear to align to previous results from our group, indicating that GABAergic activators determine a dosedependent decrease in startle amplitude (Bortolato et al, 2004) . Previous evidence suggests that animals treated with a subchronic administration of TPM exhibit dramatic startle response reductions only after exposure to stressors (Khan and Liberzon, 2004) . This finding might complement our results in suggesting that TPM might affect reactivity to environmental stimuli only at high doses or under facilitating conditions. Throughout the study, comparisons between average startle amplitudes related to blocks suggest that TPM is unable to significantly affect startle habituation. However, the protocol used in the present study was not optimized for the fine analysis of this paradigm, as shown by the fact that it also failed to detect the well-known ability Topiramate and prepulse inhibition R Frau et al of dizocilpine to impair startle habituation (Wang et al, 2003; Klamer et al, 2004) .
Intrinsic Effects of TPM on Prepulse Inhibition
Our experimental results indicate that TPM enhances PPI in a dose-dependent, inverse U-shaped fashion. Ongoing studies and previous experiments by our group suggest that neither GABAergic activators nor AMPA receptor antagonists are conducive to PPI enhancement, plausibly indicating that this effect is likely due to other mechanisms. The neurobiological significance of enhancements in baseline PPI is not fully elucidated, but it does not seem specifically related to antipsychotic activity. In fact, while the ability of antipsychotic drugs to increase baseline PPI has been occasionally shown (Depoortere et al, 1997; Sipes and Geyer, 1997; Zhang et al, 2000) , it has also been proposed to depend on experimental artifacts, since the bulk of evidence has denoted no such effect ). More interestingly, PPI enhancements might reflect an improvement in preattentional and executive functions.
In support of this possibility, such a phenomenon has been consistently shown for nicotine (Acri et al, 1994; Kumari et al, 1996) , a well known enhancer of executive behaviors (Granon et al, 2003) . Further studies are warranted to qualify the significance of TPM-mediated PPI enhancement.
Effects of TPM on Apomorphine-Induced PPI Disruption
The second experiment showed that TPM prevents apomorphine-mediated PPI disruption at doses that also inherently enhance PPI. It could be debated that the observed reversal of apomorphine-mediated PPI disruption might reflect nonspecific enhancements in baseline PPI. The finding, however, that TPM produced no such enhancement in PPI in cotreatment with dizocilpine argues strongly against this possibility. Moreover, statistical comparisons assessed significant differences in %PPI between animals treated with the combination of saline + apomorphine and the controls injected twice with saline, but not between the correspondent groups receiving TPM as pretreatment. While our findings do not allow to determine the mechanism involved in the reversal of apomorphineinduced PPI disruption mediated by TPM, they suggest that the latter might indirectly block the effects mediated by D 2 receptors. In consideration of the postsynaptic mechanism of action of apomorphine on sensorimotor gating (Mansbach et al, 1988; Geyer et al, 2001) , it is also likely that TPM might elicit its action beyond the dopaminergic synapses. Irrespective of the mechanism, our results are in agreement with several other preclinical studies showing that TPM, at comparable doses, elicits antidopaminergic effects on rodents. Previous studies indeed have shown that subchronic TPM attenuates the hyperlocomotion induced by the selective dopamine D 2 receptor agonist quinpirole (Shaldubina et al, 2002) . Furthermore, TPM has been suggested to modulate the meso-cortico and meso-limbic dopamine function (Moghaddam and Bolinao, 1994) through suppression of the extracellular release of dopamine by simultaneous facilitation of GABA transmission through a non-BDZ site and antagonizing the effects of AMPA and kainate on dopaminergic neurons (Johnson, 2005) . There is also evidence demonstrating that TPM can attenuate nicotine-associated rises in nucleus accumbens release of dopamine (Schiffer et al, 2001 ). However, a recent study by Eltayb et al (2005) reported that TPM potentiated antipsychotic-like effects of the D 2 receptor antagonist raclopride without affecting accumbal dopamine release.
Effects of TPM on Dizocilpine-Induced PPI Disruption TPM failed to reverse the PPI disruption produced by the noncompetitive NMDA receptor antagonist dizocilpine. Interestingly, Deutsch et al (2002) reported that TPM antagonized dizocilpine-induced mouse popping behavior, an animal model with relevance to NMDA receptor hypofunction in schizophrenia and predictive validity for antipsychotic activity (for a review, see Deutsch et al, 1997) .
The apparent contrast between these findings and our results might be accounted by substantial differences in behavioral traits and pharmacology between mouse popping and dizocilpine-induced prepulse inhibition reduction. Dizocilpine induces popping plausibly through a dopaminergic mechanism, since haloperidol is able to reverse this behavior in a dose-dependent manner (Deutsch and Hitri, 1993) . In contrast, the weight of evidence supports the idea that dizocilpine-mediated PPI disruption is mainly independent by dopaminergic mechanisms, although it might be potentiated by acute D 1 receptor activation (Bortolato et al, 2005) or blunted by chronic D 2 agonist treatment (Krupin and Hammer, 2005) . Indeed, atypical, but not typical antipsychotics, are able to attenuate dizocilpine-induced PPI deficits , suggesting that D 2 receptors are not critically involved in the psychotomimetic mechanisms of NMDA receptor antagonists. A second arguable difference between PPI deficit and mouse popping is that, while the explosive nature of this motor behavior is suggestive of a striatal involvement, dizocilpine fails to disrupt PPI when directly infused in nucleus accumbens (Bakshi and Geyer, 1998) .
Effects of TPM on PPI in Combination with Antipsychotics
An interesting corollary of the present study consists in the assessment of the ability of TPM to potentiate the antipsychotic-like activity of both haloperidol and clozapine on apomorphine-mediated PPI disruption. Conversely, TPM did not elicit any adjuvant effect in combination with the same drugs against the deficit in PPI mediated by dizocilpine, and even arguably countered the ability of clozapine to attenuate this latter phenomenon. As mentioned in the introduction, alterations in sensorimotor gating encompass various psychiatric disturbances, characterized by different neurobiological substrates. Schizophrenia itself is a very heterogeneous disorder, the clusters of which probably correspond to profound differences in brain mechanisms. In absence of univocal aetiologic and pathophysiological standards, nosological classifications of psychotic phenomena are exclusively based on symptomatologic criteria. The present study has shown that TPM display opposite actions in cotreatment with the atypical antipsychotic clozapine against two separate pharmacolo-gical models of filtering deficits. Although the mechanisms accounting for these differences are still elusive, our results might help provide a theoretical framework for the analysis of the differences between PPI disruption endophenotypes, which in turn might mirror diversity in substrates between clusters of psychoses or perceptual disturbances. Irrespective of the mechanisms, however, the present study is in agreement with other reports about the ability of TPM to improve the effect of other antipsychotics in schizophrenic (Drapalski et al, 2001; Deutsch et al, 2003; Tiihonen et al, 2005) as well as in bipolar patients (Chen et al, 2005) . In parallel, our findings might also help provide a tentative explanation for the numerous discrepancies in literature about the lack of efficacyFor even the hazardous effectsFof TPM in combination with other antipsychotic drugs (Dursun and Deakin, 2001; Hofer et al, 2003) . These conflicting results might indeed depend on differences in the neurobiological substrates underpinning psychotic behaviors and perceptual disfunctions. In light of this possibility, the present study encourages further investigations to explore such differences, and their relevance to the identification of improved therapeutic strategies targeting schizophrenia-spectrum and bipolar disorders.
